Dyne Therapeutics annual shares outstanding
2019
2020
2021
2022
2023
2024
2025
Dyne Therapeutics Shares Outstanding History (DYN)
Dyne Therapeutics reported 165.0M shares outstanding at the end of fiscal 2025.
View full Dyne Therapeutics company overviewDyne Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 165.0M | 62.6M | +61.21% |
| 2024 | 2024-12-31 | 102.3M | 40.8M | +66.46% |
| 2023 | 2023-12-31 | 61.5M | 5.8M | +10.48% |
| 2022 | 2022-12-31 | 55.6M | 4.1M | +7.89% |
| 2021 | 2021-12-31 | 51.6M | 6.5M | +14.40% |
| 2020 | 2020-12-31 | 45.1M | 42.5M | +1642.74% |
| 2019 | 2019-12-31 | 2.6M | — | — |
Dyne Therapeutics quarterly shares outstanding
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 165.7M | 51.3M | +44.89% |
| Q1 2026 | 2026-03-31 | 165.2M | 51.6M | +45.38% |
| Q4 2025 | 2025-12-31 | 165.0M | 62.6M | +61.21% |
| Q3 2025 | 2025-09-30 | 142.6M | 40.9M | +40.16% |
| Q2 2025 | 2025-06-30 | 114.3M | 14.2M | +14.20% |
| Q1 2025 | 2025-03-31 | 113.6M | 26.5M | +30.48% |
| Q4 2024 | 2024-12-31 | 102.3M | 40.8M | +66.46% |
| Q3 2024 | 2024-09-30 | 101.8M | 40.4M | +65.93% |
| Q2 2024 | 2024-06-30 | 100.1M | 39.1M | +64.09% |
| Q1 2024 | 2024-03-31 | 87.1M | 28.8M | +49.37% |
| Q4 2023 | 2023-12-31 | 61.5M | 5.8M | +10.48% |
| Q3 2023 | 2023-09-30 | 61.3M | 9.4M | +18.14% |
| Q2 2023 | 2023-06-30 | 61.0M | 9.3M | +17.94% |
| Q1 2023 | 2023-03-31 | 58.3M | 6.7M | +12.89% |
| Q4 2022 | 2022-12-31 | 55.6M | 4.1M | +7.89% |
| Q3 2022 | 2022-09-30 | 51.9M | 423,130 | +0.82% |
| Q2 2022 | 2022-06-30 | 51.7M | 502,020 | +0.98% |
| Q1 2022 | 2022-03-31 | 51.6M | 491,147 | +0.96% |
| Q4 2021 | 2021-12-31 | 51.6M | 6.5M | +14.40% |
| Q3 2021 | 2021-09-30 | 51.5M | 6.5M | +14.40% |
| Q2 2021 | 2021-06-30 | 51.2M | — | — |
| Q1 2021 | 2021-03-31 | 51.2M | — | — |
| Q4 2020 | 2020-12-31 | 45.1M | 42.5M | +1642.74% |
| Q3 2020 | 2020-09-30 | 45.0M | — | — |
| Q4 2019 | 2019-12-31 | 2.6M | — | — |
Dyne Therapeutics shares outstanding trends
Over the last five fiscal years, Dyne Therapeutics's shares outstanding moved from 45.1M to 165.0M, a change of 119.9M. The latest reported quarter, Q2 2026, shows 165.7M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dyne Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...
